Introduction {#s1}
============

The Chinese materia medica (CMM) is a unique healthcare system that has been successfully applied for thousands of years in East Asian countries, such as China, Japan, and Korea. Recently, the CMM has attracted increasing global attention due to their long history of clinical application, reliable therapeutic effect, and low toxicity. However, the complexity of CMMs provides a significant challenge for researchers to seek enough scientific evidences to support their efficacy [@pone.0081135-Graziose1]. Generally, most of CMMs are taken orally and the absorbed constituents are more likely to play a role in the therapeutic action *in vivo*. Thus, it is necessary to obtain the absorbed chemical profiles, evaluate their bioactivities and build the relationship between absorbed peak and bioactivity so as to identify the bioactive compositions [@pone.0081135-Chen1] and ensure the efficacy of the CMM products [@pone.0081135-Kong1]. But to solve the above problems, the three key techniques are as follows: firstly, a method with high-throughput and sensitivity is needed to analyze chemical constituents as more as possible. Rapid resolution liquid chromatography coupled with quadruple time-of-flight mass spectrometry (RRLC-Q-TOF/MS) has short analytical time and high sensitivity for identification of both known and unknown, macro and micro compounds as well [@pone.0081135-Wu1]. Secondly, a combinative bioassay that consists of an intestinal absorption test coupled with an *in vitro* bioactivity experiment is a simple, sensitive, and feasible method for evaluating CMM formulations, which allows researchers to exclude unabsorbed constituents that might produce false positive or negative pharmacological actions in bioassays and shows high sensitivity which can exhibit different activities due to the changing contents of the compounds in CMMs [@pone.0081135-Zhang1]. The third technique is data mining, with its main aim to discover hidden patterns from large data sets and to summarize them into useful information through analysis of the data from different perspectives, including statistics and artificial intelligence [@pone.0081135-Deng1].

Yuanhu Zhitong Tablet (YZT) is an example of typical and relatively simple clinical herb formula. It contains *Angelicae dahuricae Radix* and *Corydalis Rhizoma* and is widely used in the treatment of gastralgia, costalgia, headache, and dysmenorrhea caused by qi stagnancy and blood stasis [@pone.0081135-China1]. The naturally abundant compounds in these two plants have been chemically isolated and identified. Bioassays indicate that alkaloids and coumarins are the main active constituents of these plants and some of them have multiple pharmacological activities, including anti-nociceptive [@pone.0081135-Yuan1], anti-inflammatory [@pone.0081135-Chen2], anxiolytic [@pone.0081135-Leung1], spasmolytic [@pone.0081135-Hiller1], and vasorelaxation activities [@pone.0081135-Zhang1]. Vasorelaxation is very important for the treatment of pain [@pone.0081135-John1], [@pone.0081135-Liu1]. In the CMM theories, "it is the obstruction that causes the pain" and many factors can lead to migraine, such as disorders of blood vessel function, blood vessel convulsion [@pone.0081135-Shi1], [@pone.0081135-Li1]. In that case, migraine can be relieved by dredging vessels. Practitioners of Western medicine (WM) also reckon that vasospasms cause headaches (migraine) [@pone.0081135-Stillman1] and dysmenorrhea [@pone.0081135-Akerlund1].

In recent years, our research teams have carried out consistent studies in an attempt to understand action mechanisms of YZT. Firstly, the chemical fingerprint and quantitative analysis of multiple constituents were applied to the quality control of YZT [@pone.0081135-Xu1], [@pone.0081135-Zhang2]. Next, an everted intestinal sac method was used to determine the components of YZT that were absorbed by the intestine [@pone.0081135-Chen3]. These studies helped to identify the active components of YZT to further elucidate their pharmacological mechanisms. Absorption solutions of YZT obtained via using the everted sac method were full of vasorelaxant substances that produced a dose--response relationship. Moreover, the activity of intestinally absorbed YZT solution was much higher than that of one or a few dominant chemical components [@pone.0081135-Zhang1]. However, it was unclear whether the innovative combinative method of bioassay could be applied to appraise the quality of the different YZT samples and bridge the relationship between constituents and biactivity (RCB) and identified key components (KC) by data mining that relate to vasorelaxation activity. In this study, in order to better conduct the quality control of YZT products, we used the combinative method that involved an intestinal absorption test coupled with a vasorelaxation evaluation. Twelve batches of intestinally absorbed YZT solution were analyzed via RRLC-Q-TOF. Then, the RCB and KC of YZT were identified by data mining and validated by further experiments.

Experimental {#s2}
============

1. Materials and reagents {#s2a}
-------------------------

HPLC-grade acetonitrile was obtained from Tedia (Fairfield, OH, USA). Formic acid was of analytical grade and obtained from Shanghai Chemical Regent Co. (Shanghai, China). Water was purified using a Milli-Q system (Millipore, Billerica, MA, USA). Twelve batches of YZT samples that produced by different manufacturing factories were purchased from local drug stores ([**Table 1**](#pone-0081135-t001){ref-type="table"}.).
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###### A summary of the tested samples of YZT.

![](pone.0081135.t001){#pone-0081135-t001-1}

  Sample No.     Pharmaceutical factory     Batch No.   Production date
  ------------ --------------------------- ----------- -----------------
  S01                 Foci, Shanxi            11B1         2011.6.25
  S02                 Foci, Shanxi            11D3         2011.7.20
  S03           Banzhou Tianlong, Guangxi    100501        2010.5.8
  S04           Banzhou Tianlong, Guangxi    091201       2009.12.30
  05                Shuzhong, Sichuan        091203       2009.12.17
  S06               Shuzhong, Sichuan        100601        2010.6.3
  S07               Shibiao, Guangxi         100105        2010.1.8
  S08              Geruilin,Chongqing        091201        2009.12.4
  S09           Foshan Dezhong, Guangdong     10004        2010.4.29
  S10           Foshan Dezhong, Guangdong     10008        2010.9.14
  S11                 Foci, Shanxi            11D4         2011.7.25
  S12               Shuzhong, Sichuan        100502        2010.5.14

Imperatorin, isoimperatorin, osthole, protopine, berberine, palmatine, bergapten, psoralen and tetrahydropalmatine standards were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Byakangelicol, byakangelicin and coptisine were purchased from Chengdu Herbpurify Co. (Chengdu, China). Xanthotoxin, oxypeucedanin, and tetrahydroberberine were obtained from Shanghai Winherb Co. (Shanghai, China). Corydaline was supplied by Sigma Co. (Sigma, USA). Pimpinellin was from Shanghai Touto Biotech. (Shanghai, China). A-allocryptopine was purchased from Shenzhen Meihe Biotech. (Shenzhen, China). All standards were at least 98% pure and were suitable for RRLC-Q-TOF-MS analysis. Ligustrazine was purchased from Nanjing Qingze Pharmaceutical Technology Co., Ltd (Nanjing, China).

2. Sample solution preparation {#s2b}
------------------------------

The coating was removed from all samples and the remaining portion of each sample was powdered and sieved via 60 mesh. Then each sample equal to 24 g crude drug was then weighed precisely, and was extracted under reflux with 240 mL of 70% ethanol for 1 h. The extract was concentrated under reduced pressure using a rotary evaporator at 70°C, followed by dilution with Tyrode buffer (mmol/L; NaCl 136.75, KCl 3.76, NaHCO~3~ 11.90, NaH~2~PO~4~ 0.42, MgCl~2~ 1.05, CaCl~2~ 1.80, and glucose 5.56, pH 7.4) to a concentration of 0.16 g/ml. At the same time, α-allocryptopine, protopine and ligustrazine (a positive control) were directly diluted in the Tyrode buffer with the concentration of 0.58, 0.56 and 0.50 mg/ml, respectively.

3. Animals {#s2c}
----------

Adult male Sprague-Dawley rats weighing 240±10 g (from the Experimental Animal Center of Peking University Health Science Center, Beijing, China) were used for everted intestinal sac experiments and isolated vascular ring models. The animal welfare and experimental procedures complied with the Guide for the Care and Use of Laboratory Animals (National Research Council of the USA, 1996) and related ethical regulations of the China Academy of Chinese Medical Sciences. The protocols were approved by the Animal Ethics Committee of Laboratory Animals at the Institute of Laboratory Animal Resources of Beijing (Beijing, China).

4. Preparation of intestinally absorbed solution {#s2d}
------------------------------------------------

Everted sacs were prepared according to the modification of the procedure described previously [@pone.0081135-Chen3]. Briefly speaking, rat was fasted for 12 h before the experiment. Under anesthesia, the abdomen was dissected along the median line and the linea alba. Then, the jejunum and ileum were immediately removed and rinsed in ice-cold Tyrode buffer solution. Four fourteen-centimeter segments of intestine were isolated to perform the intestinal absorption study. The intestinal segments were everted using a soft silica gel tube, and then the sacs were washed with the buffer for three times, and finally each segment was ligated with cotton thread at both ends to form a sac, in which Tyrode buffer solution was filled. The filled sac was incubated in Magnus\' bath with Tyrode buffer for 5 min for equilibration, and after that the buffer was replaced with YZT solution or Ligustrazine solution. During the 2 h incubation period, the solution was maintained at 37°C and continuously aerated with O~2~/CO~2~ (95%/5%). After incubation, the sacs were removed and blotted dry using gauze. The serosal-side solutions, which contained absorbed constituents, were drained into small tubes. The intestinally absorbed solutions and blank Tyrode buffer were stored at −20°C for further analysis. Samples were prepared for RRLC-ESI-Q-TOF analysis by drying 100 µL of each solution at 37°C under a stream of nitrogen. The residue was dissolved in 100 µL of methanol, and the samples were centrifuged at 12000× *g* for 10 min. Then the supernatant was directly injected into the RRLC-ESI-Q-TOF. The remainder of each sample was used to evaluate the vasorelaxation activity of YZT *in vitro*.

5. RRLC-ESI-Q-TOF instrument, chromatographic conditions, and mass spectrometry conditions {#s2e}
------------------------------------------------------------------------------------------

Chromatographic experiments were performed using an Agilent 1200 RRLC System (Agilent Crop., Santa Clara, CA, USA) equipped with a quaternary pump, an online vacuum degasser, an auto-sample injector, and an automatic thermostatic column oven. The mobile phases were as follows: solvent A, 0.2% aqueous formic acid and solvent B, acetonitrile. Gradient elution was as follows: 0--6.0 min, 20--40% B; 6.0--8.0 min, 40--80% B; 8.0--13.0 min, 80% B; 13.0--14.0 min, 80--20% B; 14.0--15.0 min, 20% B. Elution was performed at a flow rate of 0.50 ml/min. The column was an Agilent XDB C18 maintained at 30°C, and the injection volume was 5 µl.

The TOF-MS instrument was an Agilent 6520 quadrupole TOF-MS that was equipped with an electrospray ionization source (ESI). Ionization was performed in the positive electrospray mode. Based on the best response for most compounds, the final parameters were as follows: fragmentor (150 V), Vcap (3500 V), nebulizer (30 psi), drying gas (N~2~, 10 L/min, 350°C). The TOF-MS was calibrated daily, according to the manufacturer\'s recommendations. The testing mass range was set at m/z 50--1000 with a scanning rate of 2 s^−1^. Reference masses at m/z 121.05087 (purine) and m/z 922.00980 \[hexakis (1H, 1H, 3H-tetrafluoropropoxy)-phosphazine\] (Agilent Corp.) were continually introduced along with the RRLC stream for accurate mass calibration. The collision energy for each compound varied according to the following formula: \[5×(mass/100)\]+5. For example, the collision energy of an ion with nominal m/z of 300 would be 20 V.

6. Hierarchical cluster analysis of intestinally absorbed YZT solutions {#s2f}
-----------------------------------------------------------------------

To evaluate the chemical variation of intestinally absorbed YZT solutions, hierarchical cluster analysis (HCA) was performed based on the characteristics of the peak areas in the profiles of the 34 constituent compounds. The peak areas of samples 1--12 formed a 12×34 matrix. Distances between the 12 samples were calculated using SPSS software 18.0 (SPSS Inc. USA).

7. Evaluation of vasorelaxation activity in vitro [@pone.0081135-Zhang1] {#s2g}
------------------------------------------------------------------------

### 7.1. Preparation of thoracic aorta rings {#s2g1}

After rats were killed by cervical dislocation, the thoracic aorta was carefully removed from each rat and immediately placed into ice-cold Krebs\' solution (NaCl 118.96, KCl 4.73, KH~2~PO~4~ 1.17, MgSO~4~ 1.17, NaHCO~3~ 25.0, CaCl~2~ and 2.54, glucose 11.1 mmol/L; pH 7.4). Arterial vessels were carefully prepared by removing connective fat and tissue and cut into 3 to 4 mm-long segments. The segments were mounted in an organ bath containing Krebs\' solution using 2 L-shaped stainless steel wire hooks that were inserted into the lumen. The Krebs\' solution was maintained at 37°C and O~2~/CO~2~ (95%/5%) and was continually bubbled through the solution. After incubation with no tension for 30 min, the ring segments were allowed to equilibrate for 1 h at a resting tension of 1 g and they were washed every 20 min during the period. Changes in tension were recorded by isometric transducers that were connected to a data acquisition system (Shanghai Alcott Biotech Co., LTD. Shanghai, China).

### 7.2. Bioactivity evaluation of intestinally absorbed YZT solutions on rat aortic rings with endothelium {#s2g2}

After the equilibration, the presence of endothelium was confirmed by inducing relaxation using acetylcholine (ACh, 10^−5^ mol/L) in aortic rings that had been precontracted using phenylephrine (PE, 10^−6^ mol/L). Only tissues with satisfactory endothelium activity (relaxation values, \>60%) were used in the experiments. All rings were exposed repeatedly to KCl solution (60 mmol/L) until the tension stabilized and the most contractive degree was set to 100% of relaxation in this condition. Six cumulative doses of intestinally absorbed YZT solution were then added directly to the organ bath. Doses of 50, 100, 200, 400, 800 and 1600 µl were cumulatively added at 15 min intervals. Finally, the percentage ratio of the relaxation was calculated by comparing the contractive degree using 1600 µl YZT solution to the most contractive degree using KCl solution (60 mmol/L). A total of twelve intestinally absorbed samples of YZT solution, the blank intestinally absorbed Tyrode buffer solutions and the Ligustrazine solution were evaluated. The experiment was repeated 8 times. Aortic rings were obtained from a new rat for each replication. Results of bioassay experiments were represented as mean ± S.D. The mean relaxation values from 10 samples at a dosage of 1600 µl were used to evaluate the relationship between solution constituents and bioactivity.

8. Grey relational analysis (GRA) {#s2h}
---------------------------------

GRA was proposed by Deng [@pone.0081135-Deng1] in the 1980s and is an important method of grey system theory which has been successfully applied to solve many concrete real-world problems that have complicated interrelationships between multiple variables [@pone.0081135-Chen4].

### 8.1. Principles of GRA {#s2h1}

The word "grey" in "grey system" indicates a position between "black" (extremely unknown information) and "white" (totally explicit information) and represents information that is incomplete, uncertain, or poor. In other words, a grey system is a mixture of known and unknown information. In the real world, most systems are grey rather than white or black.

GRA is based on the degree of similarity or difference in development trends between an alternative and the ideal alternative. If the trend of differences between the alternative and the ideal alternative is consistent, the 2 alternatives are strongly related [@pone.0081135-Chang1], [@pone.0081135-Gu1]. The distinguishing feature of GRA is that small data sets can be handled easily, and the quantitative and qualitative relationships between variables can be identified from numerous factors when there is insufficient information [@pone.0081135-Wu2].

### 8.2. GRA Procedure {#s2h2}

The GRA calculation process is as follows:

*Step 1. Date processing*

Like general statistical analysis methods, GRA first calls for the standardization of raw data to remove anomalies associated with different measurement units and scales by employing various techniques. This ensures that each raw data series has influence of the same degree on the dependent variables. We used average value processing, as what is shown in the following equation ([Eq. 1](#pone.0081135.e001){ref-type="disp-formula"}.) to make the raw data dimensionless.where represents the reference sequence (ideal target sequence, i.e., the optimal performance that can be achieved by any of the comparability sequences), and , , represent the comparability sequences. For convenience of presentation, we denote and as .

*Step 2. Grey relational grade (GRG) calculation*

GRG represents the level of correlation between the reference sequence and the comparability sequence , The GRG is used to describe the degree of influence that the comparability sequence exerts over the reference sequence. The GRG increases with the relative importance of a comparability sequence to the reference sequence.

GRG can be calculated as:Here . is a distinguishing coefficient, and a value of 0.5 is used in most situations. Generally, the following criteria are used, indicates a marked influence, indicates a relatively high influence, indicates a noticeable influence, indicates a small influence, and indicates a negligible influence.

*Step 3. Relational polarity analysis*

While GRG indicates how close is to (), it does not imply that the two have either a positive or negative relationship. We can solve this problem by calculating , as in [Eq. 3](#pone.0081135.e025){ref-type="disp-formula"}.If then and have a positive relationship. If then and have a negative relationship. Here, the signum function is defined as follows:

Results and Discussion {#s3}
======================

1. Optimization of the extraction conditions {#s3a}
--------------------------------------------

In order to optimize the extraction conditions, the effect of extraction method, solvent, and time on extract efficiency were investigated based on the relaxation value obtained using the combinative method of intestinal absorption coupled with vasorelaxation evaluation. Refluxing extraction was more effective than ultrasonic extraction. Further, regarding the tested ethanol concentrations, 70% ethanol was the most efficient extraction solvent. The effect of extraction time on the efficiency of refluxing extraction was investigated at 0.5, 1, 1.5 and 2 h. Finally, it was founded, at an extraction time of 1 h, the highest activity with the lowest solvent dosage could be obtained.

2. Optimization of the chromatographic and mass spectrometric conditions {#s3b}
------------------------------------------------------------------------

In order to obtain good chromatographic behavior and appropriate ionization, 4 mobile phase systems of methanol-water, acetonitrile-water, methanol-acid aqueous solution, and acetonitrile-acid aqueous solution were compared. The acetonitrile-acid aqueous solution performed better than the others. Formic acid was added into the mobile phase to improve the peak shape and restrain peak tailing, especially those of alkaloids. This was also helpful for evaluating ion response and improving the resolution of these components. The optimal solution was acetonitrile-0.2% aqueous formic acid. MS spectra were studied in both positive and negative modes. The positive mode was applied because better ion-response sensitivity was shown than in the negative mode.

3. Analytical method validation {#s3c}
-------------------------------

Six independent intestinally absorbed YZT solution samples (S6 was randomly selected) were prepared and analyzed in parallel using the above-established method to evaluate the repeatability of the method. The relative standard deviations (RSDs) of the relative retention times (RRTs) and relative peak areas (RPAs) of the common peaks were less than 1.15% and 4.78%, respectively. The precision of the method was assessed by analyzing the same sample 6 consecutive times within the same day. The RSDs of the RRTs and RPAs of the common peaks were less than 3.23% and 4.65%, respectively. Sample stability was evaluated using the same sample after 0, 4, 8, 24 and 48 h in the autosampler. The RSD of the RRTs and RPAs were less than 5%, illustrating good stability of samples in methanol over the tested period. These results indicate that the method is reliable and applicable for analysis of intestinally absorbed solutions of YZT.

4 Chemical analysis of the intestinally absorbed solutions of YZT samples {#s3d}
-------------------------------------------------------------------------

RRLC-ESI-Q/TOF) total ion chromatogram (TIC) profiles of Yuanhu Zhitong tablets and 18 standard compounds are shown in [**Figure 1**](#pone-0081135-g001){ref-type="fig"}. Thirty-four compounds were detected and identified based on retention time and MS information, as shown in [**Table 2**](#pone-0081135-t002){ref-type="table"}. Peak areas of 34 compounds of 12 intestinally absorbed YZT samples from various pharmaceutical factories, including different batches from the same manufacturer, are summarized in [**Table 3**](#pone-0081135-t003){ref-type="table"}.

![RRLC-ESI-Q/TOF chromatograms (TIC) on positive ion mode.\
(A) the intestinally absorbed YZT solutions; (B) 18 standard compounds. Peaks: 2, thalicmidine/lirioferine; 3, thalicmidine/lirioferine; 4, Tertiary alkaloid; 5, Tertiary alkaloid; 6, protopine; 9, dl-tetrahydropalmatine; 10, α-allocryptopine; 11, isoboldine; 12, coptisine; 13, tetrahydroberberine; 14, corydaline; 15, palmatine; 16, berberine; 17, dehydrocorydaline; 18, unknown; 19, byakangelicin; 20, byakangelicol; 25, xanthotoxin; 27, pimpinellin; 28, bergapten; 30, oxypeucedanin; 31, psoralen; 32, imperatorin; 33, osthole; 34, isoimperatorin; the others, unknown.](pone.0081135.g001){#pone-0081135-g001}
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###### The retention time (RT), MS data of the 34 common constituents screened out from the YZT by RRLC-Q-TOF.

![](pone.0081135.t002){#pone-0081135-t002-2}

  Peak    RT (min)   Experimental mass (m/z)   Calculated mass (m/z)         Formula                                                      MS/MS (m/z)                                                           Identification compound
  ------ ---------- ------------------------- ----------------------- --------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------
  1        2.202            314.1747                 314.1745          C~13~H~23~O~4~N~5~                         283.1320 \[M-CH~2~-OH\]^+^107.0495 \[M-C~10~H~15~N~4~O\]^+^                                           unknown
  2        2.540            342.1699                 342.1694          C~14~H~23~O~5~N~5~                        192.1013 \[M-C~9~H~10~O~2~\]^+^178.0854 \[M-C~10~H~12~O\]^+^                        thalicmidine/lirioferine [@pone.0081135-Chen4]
  3        3.198            342.1694                 342.1694          C~14~H~23~O~5~N~5~                         279.101 \[M-C~2~H~9~NO\]^+^178.0852 \[M-C~10~H~12~O~2~\]^+^                        thalicmidine/lirioferine [@pone.0081135-Chen4]
  4        3.552            356.1853                 356.1850          C~15~H~25~O~5~N~5~                                      192.1009 \[M-C~10~H~12~O~2~\]^+^                                         Tertiary alkaloid [@pone.0081135-Chang1]
  5        3.802            356.1852                 356.1850          C~15~H~25~O~5~N~5~                                      192.1013 \[M-C~10~H~12~O~2~\]^+^                                         Tertiary alkaloid [@pone.0081135-Chang1]
  6        4.206            354.1339                 354.1336            C~20~H~19~O~5~                   206.0804 \[RDA-tetrahydroisoquinoline\]^+^149.0596 \[RDA-benzene-ring\]^+^                                   protopine
  7        4.299            414.1912                 414.1918          C~18~H~23~O~3~N~9~                         368.1465 \[M-C~2~H~6~O\]^+^165.0898 \[M-C~14~H~11~N~5~\]^+^                                           unknown
  8        4.474            325.1435                 325.1442            C~15~H~16~ON~8~                  310.1182 \[M-CH~3~\]^+^294.1238 \[M-CH~3~O\]^+^279.0999 \[M-C~2~H~6~O\]^+^                                    unknown
  9        4.702            356.1860                 356.1856            C~21~H~25~O~4~N                 192.1005 \[RDA-tetrahydroisoquinoline\]^+^177.0789 \[\[RDA-benzene-ring\]^+^                            dl-tetrahydropalmatine
  10       4.729            370.1651                 370.1649            C~21~H~23~NO~5~       352.0931 \[M-H~2~O\]^+^206.0795 \[RDA-tetrahydroisoquinoline\]^+^165.0914 \[RDA-benzene-ring\]^+^                    α-allocryptopine
  11       4.912            328.1885                 328.1465            C~19~H~21~NO~4~                                         121.0638 \[M-C~15~H~11~O\]^+^                                                         isoboldine
  12       5.045            320.0920                 320.0917            C~19~H~14~NO~4~                                 292.0922 \[M-CO\]^+^262.0866 \[M-2CO-2H\]^+^                                                  coptisine
  13       5.419            340.1541                 340.1543            C~20~H~21~O~4~N                                       176.0706 \[RDA-benzene-ring\]^+^                                                   tetrahydroberberine
  14       5.495            370.2010                 370.2013            C~22~H~27~NO~4~                  207.1205 \[RDA-tetrahydroisoquinoline\]^+^191.0897 \[RDA-benzene-ring\]^+^                                   corydaline
  15       5.995            352.1543                 352.1543            C~21~H~22~NO~4~                  337.1272 \[M-CH~3~\]^+^322.1078 \[M-2CH~3~\]^+^308.1268 \[M-CH~3~-H-CO\]^+^                                  palmatine
  16       6.248            336.1228                 336.1230            C~20~H~18~NO~4~                              321.0995 \[M-CH~3~\]^+^292.0944 \[M-CH~3~-H-CO\]^+^                                              berberine
  17       6.457            366.1717                 366.1700            C~22~H~24~NO~4~     351.1445 \[M-CH~3~\]^+^336.1182 \[M-2CH~3~\]^+^322.1420 \[M-CH~3~-H-CO\]^+^308.1298\[M-2CH~3~-CO\]^+^       dehydrocorydaline [@pone.0081135-Wu2]
  18       6.764            305.1023                 305.1027          C~11~H~12~O~3~N~8~                                       203.0335\[M-C~5~H~10~O~2~\]^+^                                                          unknown
  19       7.025            357.0953                 335.1125            C~17~H~18~O~7~                     231.0156 \[M--H~2~O-C~5~H~8~O\]^+^203.0348 \[M--H~2~O-C~5~H~8~O-CO\]^+^                                  byakangelicin
  20       7.025            317.1019                 317.1020            C~17~H~16~O~6~         287.0879 \[M-CH~2~O\]^+^203.0338 \[M-CH~2~O-C~5~H~8~O\]^+^175.0402 \[M-CH~2~O-C~5~H~8~O-CO\]^+^                      byakangelicol
  21       7.322            262.1045                 262.1041           C~5~H~17~O~8~N~4~                          216.0965\[M-CH~2~O~2~\]^+^185.9843\[M-H~12~O~2~N~2~\]^+^                                             unknown
  22       7.634            554.2458                 554.2464          C~20~H~37~O~12~N~6~                                                                                                                              unknown
  23       7.910            246.2427                 246.2420            C~13~H~31~ON~3~                                            228.2312\[M-H~2~O\]^+^                                                              unknown
  24       8.159            290.2686                 290.2701              C~18~H~35~O                                             228.2320\[M-C~3~H~4~\]^+^                                                            unknown
  25       9.070            217.0466                 217.0495             C~12~H~8~O~4~                                 202.0241 \[M--CH~3~\]^+^161.0598 \[M--2CO\]^+^                                                xanthotoxin
  26       9.342            309.0731                 309.0725           C~9~H~14~O~9~N~3~                                         224.0070\[M-C~5~H~9~O\]^+^                                                            unknown
  27       9.491            247.2754                 247.0523            C~13~H~10~O~5~                               232.0355 \[M--CH~3~\]^+^217.0120 \[M-C~2~H~6~\]^+^                                              pimpinellin
  28       9.663            217.0466                 217.0495             C~12~H~8~O~4~                               202.0267 \[M--CH~3~\]^+^174.0322 \[M--CH~3~-CO\]^+^                                              bergapten
  29       9.932            339.0842                 339.0844          C~11~H~18~O~6~N~7~                           324.1187 \[M--CH~3~\]^+^178.0837 \[M-C~5~H~11~O~6~\]^+^                                             unknown
  30       10.161           287.0914                 287.0914            C~16~H~14~O~5~                                          203.0331 \[M--C~5~H~8~O\]^+^                                                        oxypeucedanin
  31       10.576           187.1734                 187.0382             C~11~H~6~O~3~                      159.1311 \[M--CO\]^+^144.0484 \[M--COCH~3~\]^+^131.0532 \[M--2CO\]^+^                                      Psoralen
  32       10.800           271.0965                 271.0965            C~16~H~14~O~4~                                           203.0314 \[M--C~5~H~8~\]^+^                                                         imperatorin
  33       11.117           245.1172                 245.1093            C~15~H~16~O~3~                                                                                                                                 osthole
  34       11.437           271.0965                 271.0965            C~16~H~14~O~4~            203.0336\[M--C~5~H~8~\]^+^159.0388\[M--C~5~H~8~-CO~2~\]^+^147.0438\[M--C~5~H~8~-2CO\]^+^                          isoimperatorin

10.1371/journal.pone.0081135.t003

###### Peak areas of thirty-four compounds from 12 batches of the YZT samples.

![](pone.0081135.t003){#pone-0081135-t003-3}

  Peak      S01         S02        S03        S04        S05        S06        S07        S08         S09         S10        S11        S12
  ------ ---------- ----------- ---------- ---------- ---------- ---------- ---------- ---------- ----------- ----------- ---------- ----------
  1       10244554   16930564     418890     332414    3942666    2059990    1120655     747919    13546055    13744838    12372915   3136280
  2       7949749     9987599    1142314    3660481    4688970     697435    1138436    9399389     9384576    10125533    10152124   2481292
  3       33700312   64824276    6702990    4053466    23353294   14888894   5252401    3076464    47050576    44901664    48581228   16425594
  4       20469648   40011020    2216500    1357947    12035808   5985759    3238425    2274434    28107396    32772130    29441340   8782729
  5       14380318   28329194    1026548     577282    5900520    2714479    1842725     790575    20550076    25968522    19358266   4767493
  6       36856000   49879568    6847007    5696668    19740582   15763828   7561199    7564052    40185440     7564052    38231020   15571606
  7       1711335     1485647     43194      36885      51993      130739     105094     52851      1041068     1414135    1211229     119994
  8       3141931     3144220     677318     392959    2028766    1312728     589205     555387     3361033     3967358    3351850    1316145
  9       42390400   86508888    37123712   37993380   32002554   19199566   33098436   70989704   62385824    70989704    61280180   20896936
  10      34411664   49026132    4849252    3627606    17187142   13540835   5551001    5015446    39142264     5015446    37562304   14107432
  11      18072188   28182211    1907938    1156952    9429763    4333017    2708047    2201167    25002894    26904977    29305297   5831961
  12      14158135   26900244    1017588    1339987    8577751    6076479    3928110    1432471    17481408     1432471    18776652   10838332
  13      4342307    11132227     971613     961612    2429294    1724858     932988     602764     6139924     4985228    7944996    1544894
  14      41778884   113993560   7765805    7637866    30821784   18377190   12713581   6182978    63463984     6182978    75402024   19333384
  15      23233662   37089924    4725501    5177430    6620499    4969553    4077647    8255664    27540176     8255664    24340236   8579587
  16      5621262    12140419     367642     395094    1588666    1836682     828854     480598     8126569    13546001    7531148    2331528
  17      88199904   139792256   10045018   10266522   23592612   18170168   12545877   7594058    109628488   178904080   97302768   31050786
  18      3251394     3146738    2411079    2045014    3143703    3222117    1025955    2023451     4407905     4853269    3408821    2731474
  19      7315382    10017907    5497550    5117611    6178704    7298941    3572644    6402335    11615372     6402335    7653924    7210558
  20      1014255     2033594     603116     519644    1055068    1236775     296196     754212     2212803     2116750    1141295    1131468
  21       199552     247769      132312     202473     138866     117894     176839     46747      208143      159810      262658     90720
  22       148469     213096      436390     558607     165571     93589      97470      104341     1313237     1392525     180031     156080
  23      1307923     981091     1694080    1082664    2096133    2586007    2002152    1393343     1661914     2382745    1933567    2251526
  24       733420     525921     1150362     651512    1311777    1636515    1152949     817735     1184827     2074517    1169948    1472406
  25       138868     315592      176341     151362     398823    1338634     514746     184070     157253      614760      211309     472431
  26       510856     472611      404223     333423     463197     524719     199312     392701     721076      798630      575375     380331
  27      8481836     5295768    7879050    6185282    10275968   11548586   10396492   7725108    14744180    21124483    9824059    11315813
  28       284307     525066      256318     210104     308832     952450     348915     145043     168709      635424      352302     340595
  29      1525608     1662515    1397379    1233607    1593201    1442143     723853    1111994     2362815     207924     1916669    1277259
  30       77103      164981      44375      30012      83877      41054      26173      15009      169819      176342      91166      26842
  31      2047545     1256449     884526    1895731     934015    1890348    2064941    1847992     5799667     7081346     790821    2048515
  32       472899     1280813    3653542    3587152    5618072    5186924    2679041     269755     4937185     1272774     709036    5348282
  33        8556       19603      10461       7867      10796       5508      11759       5362       10754       16191       8434      12334
  34        7755       36081      21122      21213      19115      21704      16501       6598       20022       20369      17372      18464

Eighteen constituents were identified by comparing their chromatographs and TOF-MS results with those of standards. These constituents are as follows: protopine (6), tetrahydropalmatine (9), α-allocryptopine (10), coptisine (12), tetrahydroberberine (13), corydaline (14), palmatine (15), berberine (16), byakangelicin (19), byakangelicol (20), xanthotoxin (25), pimpinellin (27), bergapten (28), oxypeucedanin (30), psoralen (31), imperatorin (32), osthole (33), and isoimperatorin (34). Among these, 3 compound pairs, peaks 9 and 10, 13 and 14, and 19 and 20, had almost the same retention time, but they were resulted from 2 separate constituents, based on the MS information for standard compounds. Three overlapping peaks (RT: 4.715, 5.495, and 7.050) were identified as 2 independent constituents by comparison to the chromatogram of DL-tetrahydropalmatine and α-allocryptopine, tetrahydroberberine and corydaline, byakangelicin and byakangelicol, respectively. Peaks 2, 3, 4, 5, 11, 17 were tentatively identified by comparison with MS data from related literature [@pone.0081135-Ding1]--[@pone.0081135-Zheng1] and the details were listed in [**Table 2**](#pone-0081135-t002){ref-type="table"}. However, the identity of this constituent could not be confirmed because we were unable to obtain a standard for comparison. In a previous study, we found 17 common peaks using UV measurements and 15 of these were identified in the fingerprint analysis of YZT. However, because we used a method with high sensitivity and resolution to directly analyze intestinally absorbed YZT solutions, we found 34 constituents and identified 8 more compounds in the present study than previous research.

5. Chemical assessment of the intestinally absorbed YZT solutions from 12 YZT samples using hierarchical cluster analysis {#s3e}
-------------------------------------------------------------------------------------------------------------------------

As can be seen in [**Figure 2 (A)**](#pone-0081135-g002){ref-type="fig"}, samples 5, 6 and 12 from Manufacturer C, samples 3, and 4 from Manufacturer B in Guangxi, and samples 7 and 8 from a pharmaceutical factory in Chongqing were first aggregated into 2 respective groups and were then aggregated together. Similarly, samples 1 and 2 from Manufacturer A and samples 9, 10, and 11 from Manufacturer F were included in the same group. The results indicated that chemical profiles of YZT obtained from the same factory were similar, whereas the chemical profiles of YZT obtained from different factories were significantly different, as which had been found previously [@pone.0081135-Xu1], [@pone.0081135-Zhang2]. However, it is difficult to judge the quality of CMM products solely from chemical profiles, including chemical fingerprints and the multi-marker constituents of CMM formulations.

![Chemical and bioactive profiles of the intestinally absorbed YZT solutions from 12 YZT samples.\
(A) Dendrograms of the Hierarchical Cluster Analysis based on the characteristics of 34 peaks area. (B) Vasorelaxation evaluation of the intestinally absorbed 12 YZT solutions, protopine, α-allocryptopine, blank and positive control using KCl-precontracted rat aortic rings (n = 8).](pone.0081135.g002){#pone-0081135-g002}

6. Vasorelaxation evaluation {#s3f}
----------------------------

Endothelial dysfunction was a very important reason for headache (chronic migraine) [@pone.0081135-Pedro1] and dysmenorrheal [@pone.0081135-Akdemir1]. At present, many data [@pone.0081135-Line1]--[@pone.0081135-Yetkin1] suggested that chronic migraine and cardiovascular disease had the same pathophysiological mechanisms as follows: abnormal control of systemic vascular tone, alterations in systemic arterial structure and function and impaired ability to repair systemic endothelial injury. Moreover, there existed potential relationship between the presence of migraine and congenital heart defects [@pone.0081135-Borin1]. Meanwhile, our previous research indicated that YZT was predicted to possess the pharmacological action of calcium channel receptors *in silico* which can play a crucial role in acute endothelium-dependent vasodilator responses to contract smooth muscle of the blood vessels [@pone.0081135-Xu2]. Thus, both vasorelaxation of aortic rings and basilar artery should be evaluated systemically in order to shed light on YZT samples curing chronic migraine. However, vasorelaxation of aortic rings were performed using intestinally absorbed YZT solutions and the results showed that this model in vitro exhibited very stable and sensitive in the previous research [@pone.0081135-Zhang1].

Preliminary experiments were performed to evaluate the experimental conditions of the *in vitro* vasorelaxation method and to determine the stability of samples during testing. Different concentrations of intestinally absorbed YZT solutions and different incubation times were investigated for the intestinal absorption coupled with bioactivity experiment. A dose-dependent vasorelaxant effect was produced using intestinally absorbed YZT solutions at low, middle, and high concentrations and besides, 2 h of incubation was required to reach maximal vasorelaxation [@pone.0081135-Zhang1]. In addition, intestinally absorbed YZT solutions of 6 cumulative doses were investigated and 1600 mL of the intestinally absorbed solution was selected as the maximum dose for additional experiments. Ligustrazine is an active constituent of Ligusticum chuanxiong Hort (Umbelliferae) and it has been known as a vasorelaxation compound [@pone.0081135-Kim1], so ligustrazine was chose as a positive control in the pharmacological tests, which had exhibited very good vasorelaxation (74.96±11.10) in this study.

Blood vessel activities *in vitro* were evaluated for YZT of 12 batches, the blank control and the positive control and the results were shown in [**Figure 2 (B)**](#pone-0081135-g002){ref-type="fig"}. All samples of YZT and the positive control possessed evident blood vessel activities (BVC) in contrast with the blank contol. However, BVC activity differed between batches of YZT. The maximum BVC was 83.08±12.66 and was obtained using S11, and minimum BVC was 5.11±7.17 and was obtained using S3. However, in order to distinguish YZT samples from the positive control, chemical profiles were needed to be analyzed. Fortunately, the results suggested that samples grouped by HCA from chemical profiles have similar bioactivity while samples in different groups from chemical profiles displayed very different bioactivity. Thus, the use of a combinative bioassay that includes an intestinal absorption test coupled with an *in vitro* bioactivity experiment may increase the level of CMM quality control from both chemical and bioactive profiles.

7. Bridging the relationship between constituents and vasorelaxation {#s3g}
--------------------------------------------------------------------

Using a polynomial fitting technique, we established a mathematical model to characterize the correlation between peak areas of chemical constituents of YZT and vasorelaxation. The computational simulation showed that the results from our model are fited well with the experimental data. To obtain this model, we constructed a transformation (see [Eq. 5](#pone.0081135.e038){ref-type="disp-formula"} in Section 3.7) based on GRA. was used to translate the 34-dimension raw sample data set into a 1-dimension data set, so that a single variable fitting technique could be used to solve this multivariable mathematical modeling problem. There are no related studies reporting the use of this transformation.

In order to obtain the mathematical model that establishes the correlation between constituents of YZT and vasorelaxation, the following transformation based on GRA was introduced: where are the peak areas of chemical constituents of YZT.

Based on [**Table 4**](#pone-0081135-t004){ref-type="table"} and (4), the following equation was obtained.

10.1371/journal.pone.0081135.t004

###### GRG, GRP and the standard deviation (SD).
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  peak number *i*    GRG *γ* ~0,*i*~     SD
  ----------------- ----------------- ---------
  1                    (+) 0.86748     0.09537
  2                    (−) 0.83646     0.1334
  3                    (+) 0.90366     0.09936
  4                    (+) 0.88810     0.10255
  5                    (+) 0.84050     0.11336
  6                    (+) 0.86787     0.14523
  7                    (+) 0.82585     0.1483
  8                    (+) 0.92485     0.05456
  9                    (−) 0.74752     0.12483
  10                   (+) 0.88193     0.16877
  11                   (+) 0.87691     0.07082
  12                   (+) 0.84697     0.18052
  13                   (+) 0.83907     0.12834
  14                   (+) 0.82120     0.1837
  15                   (+) 0.81349     0.13422
  16                   (−) 0.82709     0.14227
  17                   (−) 0.84082     0.12528
  18                   (−) 0.76686     0.09382
  19                   (+) 0.75483     0.12724
  20                   (−) 0.82639     0.12968
  21                   (+) 0.78033     0.15595
  22                   (−) 0.65177     0.18974
  23                   (−) 0.66073     0.08499
  24                   (−) 0.68471     0.1245
  25                   (−) 0.66170     0.18922
  26                   (−) 0.76957     0.11292
  27                   (−) 0.72378     0.12888
  28                   (−) 0.71878     0.1709
  29                   (+) 0.73035     0.13824
  30                   (−) 0.80705     0.09864
  31                   (−) 0.68944     0.14459
  32                   (−) 0.60089     0.16733
  33                   (+) 0.73804     0.14255
  34                   (+) 0.71196     0.14255

(+) and (−) represent and are positive relation and negative relation, respectively.

Samples 01--10 were used to establish the model. Using (5) and a polynomial fitting technique, the following mathematical model was obtained:where is the degree of vasorelaxation. As can be seen from [**Table 5**](#pone-0081135-t005){ref-type="table"}, the average bias ratio of modeled values to experimental data was 9.81% and 6 of the bias ratios (60%) were less than 10%.

10.1371/journal.pone.0081135.t005

###### Comparison of experimental data and modeled values.

![](pone.0081135.t005){#pone-0081135-t005-5}

  Sample NO.                              Experimental Data \[%\]   Modeled Values \[%\]   Bias Ratios \[%\]   Average Bias Ratio \[%\]
  -------------------------------------- ------------------------- ---------------------- ------------------- --------------------------
  [\#](#nt102){ref-type="table-fn"}S01             75.15                   67.81                 9.77         
  [\#](#nt102){ref-type="table-fn"}S02             75.78                   75.72                 0.08         
  [\#](#nt102){ref-type="table-fn"}S03             5.11                     5.33                 4.31         
  [\#](#nt102){ref-type="table-fn"}S04             6.47                     5.22                 19.32        
  [\#](#nt102){ref-type="table-fn"}S05             37.28                   44.75                 20.04                   9.81
  [\#](#nt102){ref-type="table-fn"}S06             28.83                   24.64                 14.53        
  [\#](#nt102){ref-type="table-fn"}S07             5.37                     6.33                 17.88        
  [\#](#nt102){ref-type="table-fn"}S08             10.76                   11.54                 7.25         
  [\#](#nt102){ref-type="table-fn"}S09             73.19                   76.71                 4.81         
  [\#](#nt102){ref-type="table-fn"}S10             80.24                   80.15                 0.12         
  [\*](#nt103){ref-type="table-fn"}S11             83.08                   82.84                 0.29                    4.16
  [\*](#nt103){ref-type="table-fn"}S12             29.28                   26.93                 8.03         

^\#^, used to perform mathematical modeling;

^\*^, used to be model validation.

In addition, samples 11 and 12 were used for assay validation. Validation results were shown in [**Table 5**](#pone-0081135-t005){ref-type="table"}. [Table 5](#pone-0081135-t005){ref-type="table"} indicated that the average bias ratio of modeled values to validation experimental data was 4.16%, and all bias ratios were less than 10%. Therefore, validation experimental data supported the theoretical predictions of the model (6). Furthermore, we could predict vasorelaxation effects of YZT by determining the peak areas of YZT constituents. From a practical point of view, this model could help us to develop software that was capable of computing the degree of expected vasorelaxation from the peak areas YZT of constituents.

8. Identifying key components of YZT for vasorelaxation {#s3h}
-------------------------------------------------------

Because only 12 samples were analyzed, general statistical analysis methods were unavailable not for data analysis. However, GRA, on the other hand, is suitable for analysis of data from "small sample sizes," and can achieve good results when evaluating with "poor information", and of uncertain systems. Thus, GRA was used to identify key components of YZT for vasorelaxation. The results of the GRA were shown in [**Table 4**](#pone-0081135-t004){ref-type="table"} (in [Eq. 2](#pone.0081135.e013){ref-type="disp-formula"}, the value of is 0.5). GRG and relational polarity analysis indicated that there were 18 components of YZT that have had increase vasorelaxation. In addition, these components could be ranked from high to low in terms of their effect on vasorelaxation as follows:

Key constituents were identified by the value of GRG which could reflect each compound for the extent of influence on vasorelaxation. Shown in [**Table 4**](#pone-0081135-t004){ref-type="table"}, the GRG values of compound 3 and 8 were greater than 0.90, which suggested that the two components had marked influence. At the same time, the GRG values of compound 1, 4, 6, 10 and 11 were at the range from 0.85 to 0.90, suggesting that the five compositions had a relatively high influence on vasorelaxation. Therefore, the seven constituents were considered as key components which could play very important roles on bioactivities. Unfortunately, only compound 6 and 10 were identified as α-allocryptopine and protopine by the standards and compound 11 were tentatively identified by related literature. The other constituents were unknown because of lacking of correlative standards and literatures. Thus, the bioactivities of key constituents (compound 6 and 10) were validated and the results suggested that α-allocryptopine and protopine exhibited very obvious vasorelaxation of 33.66±7.13 and 38.97±23.23, respectively, as shown in [**Figure 2 (B)**](#pone-0081135-g002){ref-type="fig"}. However, quantitative analysis of seventeen constituents in previous studies [@pone.0081135-Zhang2] could not control the quality of YZT samples because of lacking of quantitative information of several key constituents for bioactivity. Therefore, a series of chemical separation, structure identification and quantitative analysis of these key compositions should be carried out further research.

Conclusions {#s3i}
-----------

CMM, as a complexity system, has been confronted with great difficulties for the modernization of traditional Chinese medicine. Among them, bridging RCB and identifying KC were one (s) of the critical problems, which could increase the level of the quality control, improve the efficacy and reduce the toxicity of CMMs. In this work, the combinative bioassay *in vitro*, intestinal absorption test coupled with the bioactivity experiment, was developed to probe active constituents and their synergistic mechanism of YZT in vasorelaxation. The results indicated that chemical profiles combining with bioassay assessment, could evidently increase the level of quality control for improving the efficiency of CMMs. Main active compounds were identified and might be used as marker substances of quality control of YZT. At the same time, the correlation between constituents of YZT and vasorelaxation was established based on the mathematical model of GRA. The results suggested that it could utilize peak areas of constituents of YZT to forecast the values of vasorelaxation by the establishing mathematical model. However, many CMMs should undergo the gut flora biotransformation and the hepatic metabolism to produce some metabolites which were likely to be bioactive constituents *in vivo*. Therefore, more complex model including gut flora biotransformation, intestinal absorption and hepatic metabolism *in vitro* should be developed to probe the active constituents of CMMs. At the same time, in order to appraise the bioactivities of YZT samples systemically, vasorelaxation of basilar artery should be further performed in the future.

Our main highlight findings are as follows:

1.  The combinative bioassay, an intestinal absorption test coupled with an *in vitro* bioactivity experiment, was developed to be a simple, sensitive, and stable pharmacological method for evaluating CMM formulations. This bioassay allows for the exclusion of unabsorbed constituents that might interfere with the *in vitro* bioactivity and can be directly applied to evaluation of CMM product quality.

2.  Chemical analysis of intestinally absorbed solutions of 12 YZT samples was carried out using RRLC-Q-TOF. The high sensitivity and resolution of the RRLC-Q-TOF method resulted in the identification of 34 constituents common to all samples. The number of constituents identified in this study is obviously greater than the number previously reported for YZT chemical fingerprints [@pone.0081135-Zhang2].

3.  A mathematical model was established to bridge the correlation between the YZT chemical constituents and vasorelaxation. Because we had a small sample size, we used GRA to analyze our results. A single-variable fitting technique was used to solve the multivariable mathematical modeling problem. The model developed as part of this study can be used to develop software that can compute the expected degree of vasorelaxation from the peak areas on chromatographs of YZT constituents.

Supporting Information {#s4}
======================

###### 

**RRLC-ESI-Q/TOF chromatograms (TIC) of the intestinally absorbed YZT solutions from 12 YZT samples.** (A) sample 1, (B) sample 2, (C) sample 3, (D) sample 4, (E) sample 5, (F) sample 6, (G) sample 7, (H) sample 8, (I) sample 9, (J) sample10, (K) sample 11, (L) sample 12.

(TIF)
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Click here for additional data file.
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